K
Karen E. Mulder
Researcher at Cross Cancer Institute
Publications - 46
Citations - 1056
Karen E. Mulder is an academic researcher from Cross Cancer Institute. The author has contributed to research in topics: Colorectal cancer & Medicine. The author has an hindex of 14, co-authored 39 publications receiving 879 citations. Previous affiliations of Karen E. Mulder include University of Alberta.
Papers
More filters
Journal ArticleDOI
Body composition as an independent determinant of 5-fluorouracil-based chemotherapy toxicity.
Carla M. Prado,Vickie E. Baracos,Linda J. McCargar,Marina Mourtzakis,Karen E. Mulder,Tony Reiman,Charles A. Butts,Andrew Scarfe,Michael B. Sawyer +8 more
TL;DR: Low LBM is a significant predictor of toxicity in female patients administered 5-FU using the convention of dosing per unit of body surface area, and it is concluded that variation in toxicity between females and males may be partially explained by this feature of body composition.
Journal ArticleDOI
Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial
Michael P. Chu,J. Randolph Hecht,Dennis J. Slamon,Zev A. Wainberg,Yung-Jue Bang,Paulo M. Hoff,Alberto Sobrero,Shukui Qin,Karen Afenjar,Vincent Houe,Karen King,Sheryl Koski,Karen E. Mulder,Julie A. Price Hiller,Andrew Scarfe,Jennifer L. Spratlin,Yingjie J. Huang,Saba Khan-Wasti,Neil Chua,Michael B. Sawyer +19 more
TL;DR: This secondary analysis of TRIO-013 compares capecitabine and oxaliplatin (CapeOx) with or without lapatinib in 545 patients with ERBB2/HER2-positive metastatic gastroesophageal cancer to determine if gastric acid suppressants such as proton pump inhibitors (PPIs) may impair cape citabine efficacy.
Journal ArticleDOI
Ramucirumab (IMC-1121B): a novel attack on angiogenesis.
TL;DR: The current data on ramucirumab is reviewed, comparisons with commercially available antiangiogenic agents are made, and safety and effectiveness are compared.
Journal ArticleDOI
Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients.
Julia Sun,Alastair I. Ilich,Christina Kim,Michael P. Chu,Grace G. Wong,Sunita Ghosh,Melanie Danilak,Karen E. Mulder,Jennifer L. Spratlin,Carole R Chambers,Michael B. Sawyer +10 more
TL;DR: PPIs appear to impact RFS; this may be due to PPIs preventing capecitabine tablet dissolution and absorption preventing recurrence-free survival.
Journal ArticleDOI
Systematic review of management of colorectal cancer in elderly patients.
TL;DR: There is good evidence to support that patients = 80 years of age have similar overall survival benefits with adjuvant 5-fluorouracil (5-FU)-based chemotherapy for colon cancer and with palliative first-line monotherapy for metastatic colorectal cancer, as do younger patients.